Christian Marth, MD, PhD, and John Chan, MD, discuss frontline treatment trends and challenges in advanced endometrial cancer.
Back
Diving into Data Trends and Ongoing Research in Advanced Endometrial Cancer
Christian Marth, MD, PhD, and John Chan, MD, discuss the latest data trends in advanced endometrial cancer.
Diving into Data Trends and Ongoing Research in Advanced Endometrial Cancer
Episodes
All
All
Christian Marth, MD, PhD, and John Chan, MD, discuss data for frontline lenvatinib plus pembrolizumab in advanced endometrial cancer.
Christian Marth, MD, PhD, and John Chan, MD, discuss subgroup data for frontline lenvatinib/pembrolizumab in endometrial cancer after perioperative chemotherapy.
Christian Marth, MD, PhD, and John Chan, MD, discuss frontline chemoimmunotherapy combinations in advanced endometrial cancer.
Christian Marth, MD, PhD, and John Chan, MD, discuss antibody-drug conjugates and agents under evaluation in endometrial cancer.
Christian Marth, MD, PhD, and John Chan, MD, discuss ongoing research to watch in endometrial cancer.
Advertisement
Advertisement
Trending on OncLive
1
NAPISTAR-1-01 Data Support Rapid TUB-040 Development in Biomarker-Unrestricted Ovarian Cancer
2
FDA Grants Fast Track Designation to LYT-200 in R/R High-Risk MDS
3
Updated NCCN Guidelines Recommend Rusfertide Across Polycythemia Vera
4
Japan Approves Subcutaneous Pembrolizumab for All Approved Pembrolizumab Indications
5